← The Wire
PEPGNasdaq
PepGen Inc.
Pharmaceutical Preparations · DE · CIK 1835597
PepGen develops oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases
$102M
Market cap
$1.78
Last close
+4.7%
1D
-2.7%
5D
375K
Volume
Price · last 39 sessions-1.1%
May 4L $1.35 · H $1.93Jun 29
105
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 22, 20268-KReg FD DisclosureMay 21, 20268-KResults of OperationsMay 12, 202610-Q10-QMay 12, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KReg FD Disclosure · Company UpdateMar 30, 20268-KReg FD DisclosureMar 4, 202610-K10-KMar 4, 20268-KResults of Operations · Company UpdateMar 4, 20268-KCompany UpdateDec 8, 20258-KResults of OperationsNov 12, 202510-Q10-QNov 12, 20258-KExecutive ChangeNov 7, 20258-KReg FD DisclosureOct 1, 20258-KMaterial Agreement · Company UpdateSep 26, 2025424B5424B5Sep 25, 2025424B5424B5Sep 24, 20258-KReg FD Disclosure · Company UpdateSep 24, 20258-KResults of OperationsAug 7, 202510-Q10-QAug 7, 20258-KShareholder VoteJun 6, 20258-KReg FD Disclosure · Company UpdateMay 28, 20258-KResults of OperationsMay 8, 202510-Q10-QMay 8, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 20258-KExecutive ChangeMar 31, 20258-KExecutive ChangeMar 28, 20258-KCompany UpdateMar 4, 20258-KResults of Operations · Reg FD DisclosureFeb 24, 202510-K10-KFeb 24, 20258-KCompany UpdateJan 29, 20258-KCompany UpdateDec 16, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KCompany UpdateOct 8, 20248-KExecutive Change · Reg FD DisclosureSep 19, 20248-KCompany UpdateAug 20, 2024SC 13GSC 13GAug 12, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KReg FD Disclosure · Company UpdateJul 30, 20248-KCompany UpdateJul 2, 20248-KBylaw Amendment · Shareholder VoteJun 20, 20248-KCompany UpdateJun 11, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 2024DEFA14ADEFA14AMay 1, 2024DEF 14ADEF 14AApr 26, 2024SC 13GSC 13GApr 9, 202410-K/A10-K/AMar 29, 20248-KBylaw AmendmentMar 15, 20248-KCompany UpdateMar 13, 202410-K10-KMar 6, 20248-KResults of OperationsMar 6, 20248-KCompany UpdateMar 4, 20248-KCompany UpdateFeb 20, 2024424B5424B5Feb 7, 20248-KMaterial Agreement · Company UpdateFeb 7, 20248-KCompany UpdateJan 17, 20248-KCompany UpdateJan 8, 20248-KCompany UpdateDec 18, 20238-KExecutive ChangeNov 15, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 8, 20238-KCompany UpdateOct 12, 20238-KCompany UpdateSep 6, 20238-KCompany UpdateSep 6, 2023424B5424B5Aug 8, 20238-KMaterial AgreementAug 8, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KShareholder VoteJun 22, 20238-KCompany UpdateJun 13, 20238-KCompany UpdateMay 30, 20238-KReg FD DisclosureMay 18, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023DEFA14ADEFA14AApr 28, 2023
Insider Activity
In the 90 days to Mar 4, 2026: 3 sold $58K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Mcarthur James GPresident and CEO | Sell | 5,144 | $6.23 | $32K |
| Mar 4, 2026 | Donnelly NoelChief Financial Officer | Sell | 2,032 | $6.23 | $13K |
| Mar 4, 2026 | Streck PaulEVP, Head of R&D | Sell | 1,832 | $6.23 | $11K |
| Mar 4, 2026 | Mcarthur James GPresident and CEO | Sell | 131 | $6.33 | $829 |
| Mar 4, 2026 | Donnelly NoelChief Financial Officer | Sell | 52 | $6.33 | $329 |
| Mar 4, 2026 | Streck PaulEVP, Head of R&D | Sell | 47 | $6.29 | $296 |
| Sep 30, 2025 | Oxford Science Enterprises PlcOther | Buy | 200,000 | $3.20 | $640K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance